View
79
Download
2
Category
Preview:
DESCRIPTION
100 年度 癌症診療品質認證基準 醫院說明會. 2010.11.26. 大綱. 100 年度認證作業程序重點說明 100 年度認證基準評核重點說明 臨時動議. 申請資格. 至少需同時符合下列第一、二點條件: 一 、 新制醫院評鑑合格之醫療機構。 二 、 96 年(含)以後之任一年度 新診斷癌症個案數達 500 例以上之醫院。 三 、 醫院評鑑採院區 合併評鑑 者,癌症診療品質認證 亦須採院區合併申請認證 ,並由主要癌症治療院區提出申請。. 申請程序. - PowerPoint PPT Presentation
Citation preview
1002010.11.26
100100
96500
10031100331https://pfp.bhp.doh.gov.tw48
*
*
305530 300504020
-1. 90022.50
-100
9910010199.5.1799.1.199.4.30299.1.199.12.31101.3.15100.1.1100.12.31100.6.15100145101.6.1510114599.10.1799.5.199.9.30100.11.1 100.6.1100.9.30101.11.1101.6.1101.9.30
4(1)1 71 176 61 21 1 37l2 / 10
*-1
Rating A 10Rating A + Rating B 27Rating D + Rating E010Rating B()5Rating A Rating A + Rating B 11Rating D 3Rating E0 Rating A + Rating B 10Rating D 4Rating E 1
-2B1.22.43.23.3.33.53.6.23.6.33.104.15.1
1.11.21.31.4 2.12.2.12.2.22.32.42.52.6 3.13.23.3.13.3.23.3.33.3.43.43.53.6.13.6.23.7.13.7.23.83.93.6.33.6.43.10 4.14.24.34.44.54.6 5.15.2 6.1
*
99100210021.42.2.23.3.43.7.23.83.94.55.15.2991002
*
*
1.1 Rating E Rating D Rating C50
*
1.1Rating BC Rating AB1.275
*
1.1
*
1.1
Q A -1
Q A 106399
Q A -2
N10 N61/108[8/10*100%]=80 6[6/6*100%]=100 3/10550% 233% 5/1010100% 583% 7/10990% 6100% 9/10990% 583%11/1010100% 583% 80+100+90+90+100)/5=92% (100+83+100+83+83)/5=90%
*
1.2 1234
*
1.2Rating E Rating D Rating C Rating C
*
1.2Rating BCRating AB
*
1.21-4
*
1.2
*
1.3 Rating E Rating DRating C Rating C
*
1.3Rating BCPDCARating ABPDCA 10097-99
*
1.312
*
1.4 1. 1AJCC 2 32. 4
*
1.4 1. 1AJCC 2 3
*
1.4
*
98116C18-C21C22C33-C34C50C53C54C55C56C00 - C06C09 - C10C12 - C14 )C07-C08C11C15C16C61C67M-code9590-99922.1D2.1D1009811
*
2.1 Rating ERating DRating D Rating C
*
2.1Rating BC Rating AB3000130002
*
2.120
*
2.110097
*
2.2 2.2.1 Rating ERating DRating D95%98% 90%95% Rating C98% 95%98%
*
2.2.1Rating B98%98%95% Rating A98 96-98
*
2.2.11.991A/B100%99 A97 B97 + 97 2E+F/D100%99 D97 E9797 F9797
*
2.2.13G/H100(99) G97 H972.
*
2.2.2Rating ERating DRating D80%85%Rating C85%90%Rating B90%95%Rating A95%
*
2.2.21. I/J100 I J 2.
*
2.3 Rating E Rating DRating CRating C Rating BC() Rating AB
*
2.3
*
2.3Rating A 3 1 2 3 3.
2.3Q A QA
*
2.4 Rating E Rating DRating CRating C Rating BC Rating AB
*
2.4
*
2.41. 1234Class1~252.
2.4Q A Q1A1Q2A2
*
2.5Class1~2 Rating E Rating DRating C Rating C80
*
2.5Rating BC80~95Rating AB95
*
2.5Class1~2Stage
*
2.5123 Class1~245
*
2.51. K/L100 K L 10010%Class1-2
*
1962.13Tumor Size96983.4T Clinical T1151172.14Regional Lymph Nodes Examined991003.5N Clinical N1181193.6M Clinical M1201212.15Regional Lymph Nodes Positive1011023.7Clinical Stage Group122124
*
13.10T Pathologic T127129Other Staging System FIGO3.11N Pathologic N130131Other Staging SystemBCLC1013.12M Pathologic M132133Other Staging Systemhistology1013.13Pathologic Stage Group134136
*
2.6class0-3 Rating ERating D Rating C Rating BC Rating AB
*
2.6
*
2.61.1class 0-32class 1-225 class0334(:)56
2.6Q A Q Asummary
3.1 Rating ERating DRating CRating CRating BC
3.1Rating AB /
3.11. 1 peer review article 2 3 42. Rating A Hodgkin lymphomaBDiffuse large B cell lymphomaFollicular lymphoma
3.1Q A QRating BA
3.2 Rating ERating DRating CRating C 70 Rating BC 1. 50% 2.
3.2Rating AB 1. 2. class 1~2
3.2
class 1~2 1 2 2
3
1,00061,001-2,00092,00112
3.2
2. 1 2 33. minimum requirement12345comorbidity6 regimensdose
*
3.2
4.CB 5. summary note6. 7.
3.2Q A QCBA6
12345X6XC5/6=83%B14/667%
3.3 3.3.1 Rating E20Rating D20%40%Rating C40%60%Rating B60%80%Rating A80%
3.3.11 2()TNMAJCC
100
3.3.1
12724 11 [27+1401/ 212] 100 18/2410075 Rating B2.3.2
3.3.2 Rating E20
Rating D20%40%
Rating C40%60%
Rating B60%80%
Rating A80%
3.3.2 1 2 3()
100
3.3.2
12833211 [38+2311/ 312] 100 31/36100 86 Rating A2.3.2
3.3.3 Rating E20Rating D20%40%Rating C40%60%Rating B60%80%Rating A80% 1. 1 2 3 2. Neoadjuvant
100
3.3.3
94322 211 [34+22+12+01/ 39] 10018/2710067 Rating B2..3.2
3.3.4Rating E20Rating D20%40%Rating C40%60%Rating B60%80%Rating A80% curative intent
3.3.4curative intent1 23 1C()
100
3.3.41.
9233 2311 [32+23+13+01/ 39] 10015/2710056 Rating C2. 3.2
3.3.4Q A Q11. A1 Q2 A2 progression note
3.4 Rating ERating DRating CRating C Rating BC70%
3.4Rating AB
3.4
3.424B 150 2()
1. 2. 3. 4. 5.() 6.
7. () 8. 9. 10. 11. 12.
3.5 Rating ERating DRating CRating C 1. 2. 10%
3.5Rating BC 1. 2. 10%5% Rating AB10%20%10%
3.51.2.3. 1. 2.12303
3.5 1 2 312 3 4
3.55.1conclusion or recommendation2process6.
3.5Q A Q A
3.6 3.6.1 Rating E Rating DRating CRating C
3.6.1Rating BC
Rating AB
3.6.1 (Adjuvant)(Neoadjuvant)(Concurrent Chemoradiotherapy , CCRT)
3.6.1 1 peer review article 2 3 4
3.6.1Q A QA
3.6.2 Rating E Rating DRating CRating C 3.6.1 Prescription Rating BCPrescription Rating AB
3.6.2 1Prescription
*
3.6.3 Rating E Rating DRating CRating C Rating BC Rating AB
*
3.6.3
1.2.3.4.
*
3.6.3
1. (1)(2)(3)ready to use2.
*
3.6.3
3.4.5.
*
3.6.3
6.(spill kits)1
Class IIBClass III ()
*
3.6.3
2: () ()( )
*
3.6.4 Rating E Rating DRating CRating C Rating BC Rating AB
*
3.6.41.2. 3. 1.1 2
*
3.6.4
2.3.4.5.
6. 3.6.3
*
3.6.4
1.2.1
3.6.4Q A Qready to use2 AReady to use2
Qbarcode2Abarcode2
3.7 3.7.1 Rating ERating DRating CRating C1. 2.Rating BC Rating AB
3.7.1 1 23. permanent section
3.7.2 Rating ERating DRating CRating C Rating BC
3.7.2Rating AB
3.8 Rating E Rating DRating CRating C Rating BC Rating AB
3.8 CTMRI
3.9 Rating E Rating DRating CRating C() (curative intent) Rating BCRating C (curative intent)
3.9Rating ABRating C(curative intent) 1. 2. 3. 4.
3.91. (1) (2) CTV PTV 2.1peer review article23()4
3.93.(1)(2) 4.5.6.C7.CE
3.10 Rating E Rating DRating CRating C Rating B Rating A
*
3.10 100
*
*
4.1123/4
*
4.1Rating E Rating DRating CRating C 1. 2.
*
4.1Rating BC 1. 2. Rating AB 1. 2.
*
4.1/
*
4.11.2.Port-AHickmanPICC3./4.5.
*
4.16.7.8.3.6.4
4.1Q A QPort-APICCHickmanHickmanAQE-learningA
*
4.2 Rating E Rating DRating CRating C Rating BC Rating AB
*
4.21.2.3. 3.6.4
*
4.3 Rating E Rating DRating CRating C
*
4.3Rating B Rating A
*
4.31.2.
*
4.31.1.32.341 3.3.6.4
*
4.4Rating E Rating DRating CRating C
*
4.4Rating BC 1. 20 2. 80 20 3.
*
4.4Rating AB 1. 2.6 50%
*
4.41.()2.3.4.205.6.
*
4.41. 2. 6 6 3. 6
*
4.5 Rating E Rating DRating CRating C1.502.
*
4.5Rating BC 1.Class1~24002. Rating AB 1.2.
*
4.51.2.3.4.
*
4.51.100972.1122 3 4
*
4.53.C
*
4.6 Rating E Rating DRating CRating C Rating BC 1. 2.
*
4.6Rating AB1.2.3.4.5.
*
4.61.2.3.4.
*
4.61.2.
*
4.63.4.AintakeBMI
*
*
5.1 Rating E Rating DRating CRating C Rating BC Rating AB
*
5.1 2 PDCA
*
5.2 Rating E Rating D Rating C Rating BC Rating AB
*
5.2
5.2Q A QRating BAQA
*
*
6.1 class1~22,000A 1.IRB 2.class1~220001A
*
6.1IRB
*
3.4Q1:7.B5050241019B
Q2:55
Recommended